Lilly pulls sepsis drug Xigris, no benefit found

(Reuters) – Eli Lilly and Co withdrew its sepsis drug Xigris from all markets after the product, deemed a potential big seller when it was approved a decade ago, failed to improve survival in a clinical trial.